FDA Agrees on Registration Trial Design for Neuroprotector Privosegtor in Optic Neuritis
Agreement reached on the PIONEER-1 program: Privosegtor, which crosses the blood-brain barrier, could become the first neuroprotective therapy for treating optic neuritis.
The Gist: What's Really Happening
In reality, the FDA's Special Protocol Assessment for Privosegtor is not just a regulatory formality. It's a signal that neuro-ophthalmology has been waiting for for decades. For the first time, the FDA has confirmed in writing that the design of a registration study for a neuroprotector in acute optic neuritis is adequate for filing a new drug application. A successful completion of PIONEER-1 is all that's needed for Oculis to earn the right to an NDA submission. No additional phases, no follow-up studies, no agonizing negotiations about whether "neuroprotection has validated endpoints."
The whole difficulty of neuroprotection in the CNS has been that no one ever knew how to measure "protected neurons" in a clinical setting so that a regulator would say, "Yes, that's convincing." With Privosegtor, that ice has broken. The eye has become a window not only into the brain but also into regulatory reality: low-contrast visual acuity at three months is now recognized by the FDA as a clinically meaningful endpoint for neuroprotection. This means the path is paved not just for Privosegtor—everyone developing therapies for glaucoma, NAION, traumatic neuropathy, and even multiple sclerosis will follow it.
Timeline and Context
The story of Privosegtor is a classic biotech journey spanning several years, which I'll compress here into key milestones. First came Phase 2 ACUITY—a double-blind study at four French centers where Privosegtor at 3 mg/kg/day on a background of methylprednisolone showed a 43% reduction in GCIPL thinning compared to control and a 2.5% improvement in low-contrast visual acuity (18 letters) by month three. Then, in October 2025, Oculis raised $110 million through a stock offering at $20.25 per share—targeted funding specifically for the PIONEER program. In January 2026, the FDA granted Privosegtor Breakthrough Therapy Designation, and the EMA granted PRIME. Finally, on May 6, 2026, the signing of the SPA agreement was announced.
The context here is twofold. First, this happens amid explosive interest in neuroprotection: just in the last 48 hours, we've seen news about 3D-MIND for creating biocomputers and cell rejuvenation therapy. Second, Oculis estimates the U.S. market for acute optic neuropathies at $7 billion, and Privosegtor is currently the only one to have reached the registration stage.
Who Wins and Who Loses
Winners:
- Oculis and its CEO Riad Sherif: The company has secured both an SPA and Breakthrough Therapy Designation—two rare regulatory assets that together reduce development risks by 40–50% in the eyes of Big Pharma. If PIONEER-1 confirms the ACUITY data, Oculis will become an acquisition target with a premium of at least 70–80% over its market cap, which currently hovers around $400–500 million.
- Patients with optic neuritis unrelated to multiple sclerosis: About 30% of ON cases are not associated with MS. For them, there is currently no specific therapy beyond steroids, which speed recovery but do not protect neurons from death. Privosegtor is the first chance to preserve vision, not just accelerate recovery after an attack.
- Neuro-ophthalmology as a discipline: The SPA agreement de facto creates a precedent where low-contrast visual acuity becomes a registrable endpoint for neuroprotective drugs. This opens the door for dozens of molecules stuck between Phase 1 and 2 due to the lack of FDA-agreed efficacy criteria.
Losers:
- Developers of biosimilar steroids and generic methylprednisolone: Privosegtor is used as an add-on to steroids and, if approved, will become the standard of care. This means steroids will remain background therapy, but the margin in the ON market will shift to Oculis.
- Companies developing complement inhibitors and anti-CD20 for ON: Their logic is to suppress the inflammation that causes demyelination. Privosegtor, however, protects neurons downstream, regardless of the cause of demyelination. If the SPA confirms that structural preservation of the retina is a sufficient efficacy criterion, the "inflammatory" strategy may become less attractive from a regulatory standpoint.
What the Media Isn't Saying
Here's where it gets really interesting. Privosegtor's mechanism of action is not classical neurotrophic support, as many think. It is an activator of SGK2—serum- and glucocorticoid-regulated kinase 2. In other words, it activates an intracellular pathway normally triggered by glucocorticoids, but does so selectively, without the systemic effects of corticosteroids.
Why is this important? Because SGK2 is the cell's "crisis manager." It turns on during osmotic stress, oxidative damage, and excitotoxicity—exactly the processes that kill retinal ganglion cells in acute neuritis. Researchers at the Rothschild Foundation Hospital in Paris, led by Sophie Bonnin, showed that Privosegtor reduces the release of neurofilament light chains—a biomarker of neuroaxonal damage. This is objective evidence that the drug not only improves vision but physically protects neurons from breakdown.
But there are skeletons in the closet. The most common side effects in ACUITY were headache and acne, each occurring in two patients from the Privosegtor group, or about 10.5%. Acne with SGK2 activation is expected since the kinase is involved in regulating sodium channels in the skin, but it signals that the drug truly crosses the blood-brain barrier and acts systemically. For a five-day infusion course, this is acceptable. But for chronic use, which Oculis is already discussing in the context of other neurodegenerative diseases, safety data over 12–24 months will be needed. Currently, PIONEER-1 includes 12-month follow-up, but only for safety, not efficacy.
Forecast: Next 30 Days and 90 Days
Next 30 days (until June 7, 2026):
Oculis will ramp up patient enrollment in PIONEER-1 to full capacity. Given that site screening is already underway in at least six countries, the first patients will receive infusions by the end of May. Concurrently, negotiations with the FDA on the design of PIONEER-2 will begin—it is planned for the first half of 2026, and Oculis will likely try to expedite enrollment by expanding geography to Asia. Oculis shares could gain another 10–15% on the news of enrollment initiation.
Next 90 days (until August 7, 2026):
By this time, the first patients in PIONEER-1 will reach the three-month mark—the primary endpoint of low-contrast visual acuity. Oculis will not publish these data, but the mere fact that the study is on track and there are no safety concerns will strengthen the company's position. Concurrently, preparation for PIONEER-3 for NAION will begin, with its start expected in mid-2026. Analysts will start incorporating Privosegtor into Oculis's revenue models for 2027–2028, with figures of $600–800 million for the ON segment and an additional $400–500 million for NAION.
And most importantly: the SPA agreement for Privosegtor will create a domino effect. Other companies developing neuroprotectors (from Biogen with their ALS drugs to Annexon with complement inhibitors) will begin actively demanding SPA negotiations with the FDA, citing the Privosegtor precedent. This could shorten the development cycle for neuroprotective drugs by 2–3 years across the industry, translating into savings of $500 million to $1 billion per such asset.
— Editorial Team
